慢性乙肝合并脂肪肝应用拉米夫定治疗的病毒变异研究  

Researches into virus mutation of chronic hepatitis B overlapped fatty liver with lamivudine therapy

作　　者：邹敏超[1] 

机构地区：[1]佛山市第二人民医院感染科,广东佛山528000

出　　处：《佛山科学技术学院学报（自然科学版）》2010年第4期73-75,共3页Journal of Foshan University(Natural Science Edition)

摘　　要：目的探讨慢性乙肝合并脂肪肝患者应用拉米夫定抗病毒治疗时病毒变异的情况。方法对150病例应用拉米夫定抗病毒治疗,通过比较对照组(慢性乙肝)与单纯治疗组(慢乙肝合并脂肪肝单用拉米夫定抗病毒)以及联合治疗组(拉米夫定与联合脂肪肝治疗),观察拉米夫定抗病毒后的HBVDNA阴转率、YMDD变异率、丙氨酸氨基转移酶(ALT)、甘油三酯(TG)、体重指数(BMI)等指标的变化,以分析脂肪肝影响拉米夫定抗病毒疗效的程度。结果治疗2年:对照组HBVDNA阴转率68%,YMDD变异率30%;单纯治疗组HBVDNA阴转率40%,YMDD变异率58%;联合治疗组HBVDNA阴转率70%,YMDD变异率28%。结论慢乙肝合并脂肪肝患者应用拉米夫定抗病毒时联合脂肪肝治疗,能明显提高HBVDNA阴转率、降低YMDD变异率(P<0.05)。Objective To investigate the virus mutation of chronic hepatitis B overlapped fatty liver in anti-virus therapy with lamivudine. Methods Compared with the arv treatment group （chronic hepatitis b） and simple treatment group （CHB overlapped NAFLD with lamivudine therapy） and joint treatment group （lamivudine therapy with fatty therapy）, 150 patients who have received the lamivudine therapy were chosen to observe the index changes of the negative turn from HBVDNA, YMDD mutation, alanine amino shift enzyme （ALT）, triglycerides （TG） and body mass index （BMI） after lamivudine antiviral therapy, and analyze the effect on efficacy of lamivudine antiviral therapy with NAFLD. Results After a two-year treatment, the negative turn from HBVDNA and YMDD mutation of the arv group is 68% and 58% respectively. After a two-year treatment,the negative turn from HBVDNA and YMDD mutation of the arv group, the simple treatment group and the joint treatment group are 68% and 30%, 40% and 58% and 70% and 28 respectively Conclusion The negative turn from HBVDNA obviously increased while YMDD （P〈0. 05） mutation reduced when the patients received a lamivudine treatment combined with the fatty liver treatment.

关 键 词：乙型肝炎 脂肪肝 拉米夫定 病毒变异 

分 类 号：R575.1[医药卫生—消化系统]